Trius Therapeutics, Inc. - Product Pipeline Review - Q1 2011

Trius Therapeutics, Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Trius Therapeutics, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Trius Therapeutics, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Trius Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Trius Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Trius Therapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Trius Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Trius Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Trius Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Trius Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Trius Therapeutics, Inc. and identify potential opportunities in those areas. SHOW LESS READ MORE >

List of Tables
List of Figures
Trius Therapeutics, Inc. Snapshot
Trius Therapeutics, Inc. Overview
Key Information
Key Facts
Trius Therapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
Trius Therapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Trius Therapeutics, Inc. – Pipeline Products Glance
Trius Therapeutics, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Trius Therapeutics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Trius Therapeutics, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Trius Therapeutics, Inc. – Drug Profiles
Torezolid
Product Description
Mechanism of Action
R&D Progress
Torezolid
Product Description
Mechanism of Action
R&D Progress
Torezolid
Product Description
Mechanism of Action
R&D Progress
GyrB/ParE Program
Product Description
Mechanism of Action
R&D Progress
Marine Natural Products Program
Product Description
Mechanism of Action
R&D Progress
Trius Therapeutics, Inc. – Pipeline Analysis
Trius Therapeutics, Inc. – Pipeline Products by Therapeutic Class
Trius Therapeutics, Inc. - Pipeline Products By Target
Trius Therapeutics, Inc. – Pipeline Products by Route of Administration
Trius Therapeutics, Inc. – Pipeline Products by Molecule Type
Trius Therapeutics, Inc. – Recent Pipeline Updates
Trius Therapeutics, Inc. – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Trius Therapeutics, Inc., Deals Volume Summary, 2004 to YTD 2011
Trius Therapeutics, Inc., Deals Summary By Region, 2004 to YTD 2011
Trius Therapeutics, Inc., Deals Summary, 2004 to YTD 2011
Trius Therapeutics, Inc. Detailed Deal Summary
Venture Financing
Trius Therapeutics Secures $30 Million In Series B Financing
Trius Therapeutics Secures $20 Million In Series A Financing
Equity Offering
Trius Therapeutics Completes Initial Public Offering For $50 Million
Licensing Agreements
Dong-A Pharmaceutical Enters Into Licensing Agreement with Trius Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Trius Therapeutics, Inc. – Pipeline by Therapy Area and Indication, 2011
Trius Therapeutics, Inc. – Pipeline by Stage of Development, 2011
Trius Therapeutics, Inc. – Monotherapy Products in Pipeline, 2011
Trius Therapeutics, Inc. – Phase III, 2011
Trius Therapeutics, Inc. - Phase II, 2011
Trius Therapeutics, Inc. - Phase I, 2011
Trius Therapeutics, Inc. - Pipeline By Therapeutic Class, 2011
Trius Therapeutics, Inc. - Pipeline By Target, 2011
Trius Therapeutics, Inc. – Pipeline By Route of Administration, 2011
Trius Therapeutics, Inc. – Pipeline By Molecule Type, 2011
Trius Therapeutics, Inc. – Recent Pipeline Updates, 2011
Trius Therapeutics, Inc., Deals Summary, 2004 to YTD 2011
Trius Therapeutics, Inc., Deals Summary by Region, 2004 to YTD 2011
Trius Therapeutics, Inc., Deals Summary, 2004 to YTD 2011

List of Figures
Trius Therapeutics, Inc. – Pipeline by Therapy Area and Indication, 2011
Trius Therapeutics, Inc. – Pipeline by Stage of Development, 2011
Trius Therapeutics, Inc. – Monotherapy Products in Pipeline, 2011
Trius Therapeutics, Inc. – Pipeline By Therapeutic Class, 2011
Trius Therapeutics, Inc. - Pipeline By Target, 2011
Trius Therapeutics, Inc. – Pipeline By Route of Administration, 2011